Related Experiment Video
Updated: Jun 21, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Clevudine for hepatitis B.
1Medical Information Department, Prous Science, Barcelona, Spain. leifanderson@aol.com
Drugs of Today (Barcelona, Spain : 1998)
|July 9, 2009
Summary
Clevudine offers sustained hepatitis B virus (HBV) DNA suppression post-treatment. Its unique mechanism, long half-life, and cccDNA reduction show promise for chronic HBV infection management.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection remains a significant global health concern.
- Current treatments aim for viral suppression and improved liver health.
- Novel therapeutic agents with distinct mechanisms are crucial for managing chronic HBV.
Purpose of the Study:
- To review the characteristics and efficacy of clevudine for treating chronic hepatitis B.
- To highlight clevudine's unique pharmacological properties and mechanism of action.
- To summarize clinical trial data and ongoing research for clevudine.
Main Methods:
- Comprehensive literature review of clevudine through November 2008.
- Inclusion of data from phase III trials comparing clevudine to placebo.
- Consideration of ongoing and planned comparative trials against other antivirals.
Main Results:
- Clevudine demonstrated sustained HBV DNA suppression after treatment cessation.
- Phase III trials showed significant undetectable HBV DNA rates and normal liver enzymes compared to placebo.
- Animal models indicated significant reduction of covalently closed circular DNA (cccDNA).
Conclusions:
- Clevudine possesses a unique activation pathway and inhibits multiple steps in the HBV lifecycle.
- Its long half-life and sustained efficacy support its role in hepatitis B treatment.
- Further large-scale trials are ongoing to establish its comparative effectiveness against other agents.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...